👇🏼👇🏼👇🏼

Hear, hear!

New JAMA Network Open study finds that 1 in 5 cancer drugs were approved through U.S. FDA's Real-Time Oncology Review program (shorter review, faster approval), many of which were based on surrogate markers - Did FDA ask for confirmation of clinical benefit?jamanetwork.com/journals/jaman…

Health Care Lobbying and Oncology in USA
acrobat.adobe.com/id/urn:aaid:sc… via Aaron Mitchell & Ryan Nipp, MD, MPH et al Susan Bewley James Larkin

We looked at lobbying spending by oncology organizations!

Spending by advocacy organizations remains the highest, but spending by physician organizations (eg., ASCO) and PPS-exempt cancer centers has recently increased.
New in Journal of the @NCCN
Ryan Nipp, MD, MPH
jnccn.org/view/journals/…

Looking forward to presenting findings on differences in cancer treatment between Medicare Advantage and Medicare FFS patients, with JeahJung & co on the team! #ASCO24

Looking forward to presenting our new findings at #ASCO24 !
How much industry money do NCI cancer centers receive, relative to public/NCI funding? 🤔

Can we stop using BMA for SSE reduction in the mHSPC setting. Thank you ⁦Michael Morris⁩ for this important work.

Really important work and I am looking forward to reading in detail!

Extending prior work on physician receipt of industry gifts, the key findings are increasing prescribing of cancer drugs without improvement in patient survival:

lol, the algorithms can’t yet recognize a health services researcher in a basic science world.

People often ask me what physician-industry COI is like in Europe. My impression is that it is more similar to US than different...and they lack a system like Open Payments that at least provides some degree of transparency.
New work by James Larkin &co:
sciencedirect.com/science/articl…

💊 ❌ Majority of cancer drugs approved in the FDAs accelerated approval pathway do not improve patient survival or QOL

Important reminder for KOLs to honestly evaluate trial results & limitations

JAMA Eddie Cliff

#MedTwitter #oncology

jamanetwork.com/journals/jama/…

Check out our new study BMJMedicine to learn about how NCCN guidelines recommend oncology drug treatments with U.S. FDA accelerated approval. Yale_CRRIT Reshma Ramachandran Joseph Ross Joshua D. Wallach Josh Skydel Aaron Mitchell

bmjmedicine.bmj.com/content/3/1/e0…

Maryam Mooghali, MD, MSc and colleagues analyse the consistency of National Comprehensive Cancer Network's accelerated approval status, post approval confirmatory trials, and guideline recommendation alignment with post approval confirmatory trial results.
bit.ly/4aKFXgL

Out now STAT half of cancer drugs granted accelerated approval don’t show improved survival in subsequent confirmatory trials - also covered @CRRIT findings of NCCN guidelines not consistently updated when confirmatory trials fail to confirm benefit:
statnews.com/2024/04/07/can…

Industry Payments to US Physicians
youtu.be/dBj9e70F7_o?si… via Aaron Mitchell

“The guidelines should explicitly state the approval pathway…of the recommended drug and provide information about the strength of evidence supporting the approval.”

Maryam Mooghali, MD, MSc in The Lancet Oncology today:

thelancet.com/journals/lanon…

Nearly 1 in 4 adults who were disenrolled from Medicaid during the unwinding process report being uninsured now, our latest survey shows.

View the breakdown of current health coverage status among those disenrolled: bit.ly/3UeqHmN